Abivax Sa ADR (ABVX)

$7.05 +0.40 (6.02%)
Market Cap 421.97M
Revenue (ttm) 0.00
Net Income (ttm) -190.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -10.44
Volume 180,500
Avg Vol 194,250
Day's Range N/A - N/A
Shares Out 63.45M
Stochastic %K 70%
Beta 0.01
Analysts Strong Sell
Price Target $35.00

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporat...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 53 83 09 63
Address:
7-11 boulevard Haussmann, Paris, France
PenkeTrading
PenkeTrading Jun. 4 at 11:55 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Abivax SA American Depositary Shares. Is that bullish or bearish? $ABVX #RsiOverbought #NASDAQ
0 · Reply
mikesterz7
mikesterz7 Jun. 2 at 8:27 PM
$ABVX Abivax (ABVX, Financial) reports a net loss of EUR 52.4M for Q1 2025, with operating losses widening to EUR 47.2M from EUR 44.7M in Q1 2024. Research and Development expenses rose by EUR 3.6M to EUR 39.3M, largely due to Crohn's Disease clinical program advancement. The company's cash position decreased significantly to EUR 103.6M from EUR 144.2M as of December 2024.
0 · Reply
ChessGM
ChessGM May. 28 at 1:46 AM
$ABVX https://open.substack.com/pub/chessgmstocks/p/top-10-holdings-from-biotech-hedge?r=2hmnhp&utm_campaign=post&utm_medium=web&showWelcomeOnShare=false
0 · Reply
Armonica423
Armonica423 May. 7 at 2:18 AM
$ABVX CYDY
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Apr. 30 at 10:41 AM
WATCHLIST APR 30 2025. $GH Guardant Health Presents Data From Study Showing That Methylation-Based Shield MCD Test Showed High Specificity And Clinically Meaningful Sensitivity Across Ten Tumor Types $QGEN QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control $ENVX B. Riley Securities Maintains Buy on Enovix, Lowers Price Target to $12 $ABVX Abivax Completes Enrollment For Phase 3 ABTECT Trials In Patients With Moderately To Severely Active Ulcerative Colitis $LEG Leggett & Platt shares are trading higher Tuesday. The company on Monday reported better-than-expected Q1 EPS results and raised its FY25 EPS guidance.
0 · Reply
_www_larval_com_
_www_larval_com_ Apr. 9 at 7:52 PM
$BLIV 11%[96%] $ABVX -9%[10%] $NAOV 6%[-11%] $DXF -5%[15%] $AREB -5%[-31%] most notable movement into the final minutes of trading.
0 · Reply
LewisDaKat
LewisDaKat Apr. 5 at 6:55 PM
News $ABVX (ABVX) Investment Analysis and Advice https://marketwirenews.com/news-releases/-abvx-investment-analysis-and-advice-7055611652583202.html $ABVX
0 · Reply
Lowlow1
Lowlow1 Apr. 1 at 6:17 PM
$ABVX Agmh very good price to jump in at 0.042 has to get to a dollar soon if I post again mybad we are holding over here,
0 · Reply
LewisDaKat
LewisDaKat Mar. 27 at 12:55 AM
$ABVX News Article Abivax publishes financial reports with the French and U.S. securities regulatory agencies https://marketwirenews.com/news-releases/abivax-publishes-financial-reports-with-the-french-a-5025078339786107.html $ABVX
0 · Reply
mikesterz7
mikesterz7 Mar. 24 at 8:12 PM
$ABVX Abivax has released its full-year 2024 financial results, reporting a cash balance of EUR 144.2M as of December 31, 2024, providing runway into Q4 2025. The company's operating income increased to EUR 12.5M, up from EUR 4.6M in 2023. R&D expenses rose to EUR 146.5M, primarily due to the advancement of Phase 3 ABTECT clinical trials for obefazimod in ulcerative colitis (UC). G&A expenses increased to EUR 32.9M, reflecting organizational growth and dual-listing costs. The company reported a EUR 3.3M net financial loss. Key upcoming milestones include: Full enrollment in Phase 3 ABTECT trial expected in Q2 2025 Top-line results from 8-week induction trials anticipated in Q3 2025 Completion of 44-week maintenance trial in Q2 2026
0 · Reply
Latest News on ABVX
Abivax Announces Results of its June 6, 2025 Annual General Meeting

Jun 11, 2025, 4:00 PM EDT - 14 days ago

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Presents First Quarter 2025 Financial Results

Jun 2, 2025, 4:00 PM EDT - 23 days ago

Abivax Presents First Quarter 2025 Financial Results

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

Jun 2, 2025, 11:00 AM EDT - 23 days ago

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

JNJ LLY

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Apr 29, 2025, 4:05 PM EDT - 2 months ago

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Apr 22, 2025, 4:05 PM EDT - 2 months ago

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Apr 22, 2025, 4:00 PM EDT - 2 months ago

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Mar 26, 2025, 5:05 PM EDT - 3 months ago

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Mar 24, 2025, 3:30 AM EDT - 3 months ago

Abivax Announces Full Year 2024 Financial Results

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Feb 21, 2025, 2:30 AM EST - 4 months ago

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax Publishes 2025 Financial Calendar

Jan 28, 2025, 2:30 AM EST - 5 months ago

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Jan 23, 2025, 4:05 PM EST - 5 months ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Jan 9, 2025, 11:35 AM EST - 5 months ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Dec 23, 2024, 4:05 PM EST - 6 months ago

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 19, 2024, 4:30 PM EST - 7 months ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Nov 14, 2024, 4:01 PM EST - 7 months ago

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Nov 13, 2024, 4:01 PM EST - 8 months ago

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Oct 7, 2024, 4:01 PM EDT - 9 months ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Oct 3, 2024, 4:01 PM EDT - 9 months ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Oct 3, 2024, 2:31 AM EDT - 9 months ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Sep 26, 2024, 2:30 AM EDT - 9 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Sep 25, 2024, 4:01 PM EDT - 9 months ago

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax presents first-half 2024 financial results

Sep 9, 2024, 4:01 PM EDT - 10 months ago

Abivax presents first-half 2024 financial results

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Aug 6, 2024, 2:30 AM EDT - 11 months ago

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Abivax Provides Operational and Key Program Update

Jul 15, 2024, 4:00 PM EDT - 1 year ago

Abivax Provides Operational and Key Program Update

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

Jun 4, 2024, 4:10 PM EDT - 1 year ago

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 1:25 PM EDT - 1 year ago

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Abivax reports 2023 financial results and operational update

Apr 2, 2024, 2:30 AM EDT - 1 year ago

Abivax reports 2023 financial results and operational update

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

Feb 13, 2024, 2:50 AM EST - 1 year ago

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

Oct 26, 2023, 4:00 AM EDT - 1 year ago

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

Oct 24, 2023, 4:15 PM EDT - 1 year ago

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

Oct 21, 2023, 1:25 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

HG JL MNR MVRK NCL WAY WBUY

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

Oct 20, 2023, 10:00 AM EDT - 1 year ago

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

Oct 20, 2023, 9:15 AM EDT - 1 year ago

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Oct 20, 2023, 3:00 AM EDT - 1 year ago

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Abivax increases size of Nasdaq uplisting deal

Oct 19, 2023, 6:48 AM EDT - 1 year ago

Abivax increases size of Nasdaq uplisting deal

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range

Oct 18, 2023, 6:17 PM EDT - 1 year ago

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range

Abivax Readies $250 Million U.S. IPO For Drug Pipeline

Oct 18, 2023, 5:20 PM EDT - 1 year ago

Abivax Readies $250 Million U.S. IPO For Drug Pipeline

Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

Oct 16, 2023, 12:00 PM EDT - 1 year ago

Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut

Oct 14, 2023, 4:40 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut

BIRK ATPC GMM LRHC MNR PMEC PMNT

Abivax SA Starts U.S. IPO Process

Oct 3, 2023, 1:05 PM EDT - 1 year ago

Abivax SA Starts U.S. IPO Process

PenkeTrading
PenkeTrading Jun. 4 at 11:55 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Abivax SA American Depositary Shares. Is that bullish or bearish? $ABVX #RsiOverbought #NASDAQ
0 · Reply
mikesterz7
mikesterz7 Jun. 2 at 8:27 PM
$ABVX Abivax (ABVX, Financial) reports a net loss of EUR 52.4M for Q1 2025, with operating losses widening to EUR 47.2M from EUR 44.7M in Q1 2024. Research and Development expenses rose by EUR 3.6M to EUR 39.3M, largely due to Crohn's Disease clinical program advancement. The company's cash position decreased significantly to EUR 103.6M from EUR 144.2M as of December 2024.
0 · Reply
ChessGM
ChessGM May. 28 at 1:46 AM
$ABVX https://open.substack.com/pub/chessgmstocks/p/top-10-holdings-from-biotech-hedge?r=2hmnhp&utm_campaign=post&utm_medium=web&showWelcomeOnShare=false
0 · Reply
Armonica423
Armonica423 May. 7 at 2:18 AM
$ABVX CYDY
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Apr. 30 at 10:41 AM
WATCHLIST APR 30 2025. $GH Guardant Health Presents Data From Study Showing That Methylation-Based Shield MCD Test Showed High Specificity And Clinically Meaningful Sensitivity Across Ten Tumor Types $QGEN QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control $ENVX B. Riley Securities Maintains Buy on Enovix, Lowers Price Target to $12 $ABVX Abivax Completes Enrollment For Phase 3 ABTECT Trials In Patients With Moderately To Severely Active Ulcerative Colitis $LEG Leggett & Platt shares are trading higher Tuesday. The company on Monday reported better-than-expected Q1 EPS results and raised its FY25 EPS guidance.
0 · Reply
_www_larval_com_
_www_larval_com_ Apr. 9 at 7:52 PM
$BLIV 11%[96%] $ABVX -9%[10%] $NAOV 6%[-11%] $DXF -5%[15%] $AREB -5%[-31%] most notable movement into the final minutes of trading.
0 · Reply
LewisDaKat
LewisDaKat Apr. 5 at 6:55 PM
News $ABVX (ABVX) Investment Analysis and Advice https://marketwirenews.com/news-releases/-abvx-investment-analysis-and-advice-7055611652583202.html $ABVX
0 · Reply
Lowlow1
Lowlow1 Apr. 1 at 6:17 PM
$ABVX Agmh very good price to jump in at 0.042 has to get to a dollar soon if I post again mybad we are holding over here,
0 · Reply
LewisDaKat
LewisDaKat Mar. 27 at 12:55 AM
$ABVX News Article Abivax publishes financial reports with the French and U.S. securities regulatory agencies https://marketwirenews.com/news-releases/abivax-publishes-financial-reports-with-the-french-a-5025078339786107.html $ABVX
0 · Reply
mikesterz7
mikesterz7 Mar. 24 at 8:12 PM
$ABVX Abivax has released its full-year 2024 financial results, reporting a cash balance of EUR 144.2M as of December 31, 2024, providing runway into Q4 2025. The company's operating income increased to EUR 12.5M, up from EUR 4.6M in 2023. R&D expenses rose to EUR 146.5M, primarily due to the advancement of Phase 3 ABTECT clinical trials for obefazimod in ulcerative colitis (UC). G&A expenses increased to EUR 32.9M, reflecting organizational growth and dual-listing costs. The company reported a EUR 3.3M net financial loss. Key upcoming milestones include: Full enrollment in Phase 3 ABTECT trial expected in Q2 2025 Top-line results from 8-week induction trials anticipated in Q3 2025 Completion of 44-week maintenance trial in Q2 2026
0 · Reply
Investor3251987
Investor3251987 Mar. 23 at 3:13 PM
$ABVX $HOLO https://coincentral.com/microcloud-hologram-holo-stock-surge-over-40-after-strong-2024-financial-results/ 🚀
0 · Reply
27R
27R Mar. 21 at 2:44 PM
$ABVX earnings on deck. Analysts eye pipeline catalysts & operational updates amid recent volatility. Options pricing suggests muted near-term moves despite 35% YTD gain. Focus stays on Phase 3 readiness and partnership traction. Key thresholds: $15-$18 strike clustering.
0 · Reply
JarvisFlow
JarvisFlow Mar. 20 at 11:00 AM
Morgan Stanley has adjusted their stance on Abivax ( $ABVX ), setting the rating to Equal-Weight with a target price of 12.
0 · Reply
JarvisFlow
JarvisFlow Mar. 18 at 2:28 PM
Citizens Capital Markets has updated their rating for Abivax ( $ABVX ) to Market Outperform with a price target of 33.
0 · Reply
_www_larval_com_
_www_larval_com_ Mar. 13 at 5:37 PM
$ABVX has reverted 5% higher to -4% (~744Kv) in the last few minutes, follow for more volatility.
0 · Reply
_www_larval_com_
_www_larval_com_ Mar. 10 at 6:08 PM
$ABVX just stumbled -5% lower to -22% (~962Kv) a few minutes ago, follow for more volatility.
0 · Reply
Rassy34
Rassy34 Feb. 28 at 9:06 PM
$ABVX what happened in Paris with the french original shares today ? 890k trading volume - that's 27x average
1 · Reply
n9e7t2z5a9c4h7
n9e7t2z5a9c4h7 Feb. 23 at 2:03 PM
$ABVX
0 · Reply
jParkz
jParkz Feb. 21 at 6:30 PM
News $ABVX Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 https://marketwirenews.com/news-releases/abivax-to-host-key-opinion-leader-kol-webcast-on-mar-6836238494903873.html $ABVX
0 · Reply
TheLearnerEarner
TheLearnerEarner Feb. 7 at 6:42 PM
$ABVX ✅ HUGELY UNDERVALUED stock swing trade - healthcare - small cap - 3/9 F-Score - 4.7x relative volume - 5x analysts buy rating - has more assets than liabilities - revenue is forecast to grow per year - short term gains (with potential for a medium term upgrade) 💱 RSI: 36.13 (oversold momentum) 📊🌠 Analysts Price Target: $32.50 - $50.00 (441% - 733.33% above Price) 🌟 Range (12m) $5.50 - $17.02 💰 NEWSDESK (last recent positive article) 📰 https://www.stocktitan.net/news/ABVX/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-8d3xtlf8tbg9.html
0 · Reply
Zkoko_Bio
Zkoko_Bio Jan. 31 at 2:18 PM
$APTO $MVST $KAVL $SGN $ABVX What do you like about $ABVX ?
0 · Reply